Skip to Main Content

A Food and Drug Administration meeting scheduled for next week to review a Chinese-developed cancer immunotherapy is likely to be challenging for drug sponsor Eli Lilly, following skeptical comments published Friday evening by the U.S. agency’s top cancer regulator.

Writing in Lancet Oncology, the FDA’s Richard Pazdur described imported cancer drug data from China as a “bridge over troubled waters.” As an example, Pazdur singled out sintilimab, an anti-PD-1 checkpoint inhibitor developed by the China-based drugmaker Innovent and licensed to Lilly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment